Does Cardarine Actually Cause Cancer?

Cardarine has one of the more polarizing reputations in the performance space, and most of the debate misses what actually matters.

The people who say it causes cancer point to a real study. The people who say that study is irrelevant because of the doses are also pointing at something real. But both groups are stopping short of the actual question, which is whether we have enough information to say anything useful about human risk at the doses people actually use.

To answer that honestly, you need to understand what cardarine does at the biological level.

Cardarine activates something called PPARdelta, which is a receptor inside your cells that functions like a master switch for energy source selection. When PPARdelta gets activated, it turns on genes that shift your cells toward burning fat instead of glucose, and it also promotes the building of new mitochondria. This is why cardarine produces the endurance and fat oxidation effects it is known for. The receptor is real, the mechanism is real, and the effects downstream of it are real.

The cancer concern traces back to a GlaxoSmithKline study from 2007. They ran two separate two-year carcinogenicity studies, one in rats and one in mice, which is the standard protocol for evaluating whether a compound causes cancer before moving it forward in pharmaceutical development. Two years is essentially the entire adult lifespan of a rat, so this is as close as animal research gets to lifetime exposure. They found tumors across multiple organ systems including the liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs. The signal appeared in both species. That is not a borderline result. That is the kind of finding that ends drug development, and it did.

Now, the dose question is where people tend to either dismiss the concern entirely or fail to think it through carefully.

When you convert animal doses to human equivalents, the FDA-preferred method uses body surface area normalization rather than simple weight scaling, because metabolic rate and drug processing differ between species in ways that weight alone does not capture. When you apply that conversion to the lowest dose that produced tumors in female rats, you get roughly 39 milligrams per day for a 175 pound person. For males it comes out to around 64 milligrams per day. Most people using cardarine are taking somewhere between 10 and 20 milligrams, so there is a gap.

But the gap matters less than people think, for two reasons.

The first is that the gap is only about two to six times the doses people actually use, depending on sex and which study arm you reference. In pharmaceutical development, the standard safety threshold before a compound is considered reasonably safe is a ten-fold margin between the effective human dose and the lowest dose that caused harm in animals. Cardarine never came close to clearing that bar.

The second reason is more important. The researchers never found a dose where tumors did not appear. In a standard carcinogenicity study, you test multiple doses specifically so you can identify a no-effect level, a threshold below which the compound appears safe. There was no such threshold found in the cardarine data. At every dose they tested, across both species, the tumor signal was present. That is the part of the story that gets left out when people argue the doses were too high to matter.

There is also something worth understanding about how PPARdelta and cancer interact at the cellular level, because it changes how you should think about cardarine versus the natural PPARdelta activation you get from exercise.

Exercise activates PPARdelta. So in one sense, cardarine is mimicking a natural pathway. But the mechanism is not the same as the downstream effects being identical, and this distinction matters enormously. When exercise activates PPARdelta, it also activates something called AMPK, which stands for AMP-activated protein kinase and functions as a kind of molecular brake on the parts of PPARdelta signaling that can promote tumor growth. Research published in the Journal of Biological Chemistry in 2021 showed that AMPK phosphorylates PPARdelta at a specific site, serine 50, and that this modification suppresses the pro-tumorigenic transcriptional programs while leaving the metabolic benefits largely intact. Cardarine activates PPARdelta directly, as an agonist, without necessarily engaging that same AMPK-mediated brake. So the fact that exercise activates the same receptor does not tell you that cardarine carries the same risk profile as exercise. The co-activation pattern is different, and that difference may be exactly what the cancer studies are detecting.

There was one human randomized controlled trial published in 2012 that tested cardarine in 268 subjects at up to 10 milligrams per day for 12 weeks. No serious adverse events were reported. But 12 weeks is nowhere near long enough to detect cancer signal. Tumors do not appear in 12 weeks. The two-year rat studies exist precisely because short-term studies cannot answer the carcinogenicity question, and no equivalent long-duration human study has ever been done, and almost certainly never will be, because no ethics board would approve intentionally exposing healthy humans to a compound with this preclinical profile for the years it would take to generate meaningful data.

That is the actual state of the evidence. A clean short-term human trial that cannot answer the cancer question, and two long-term animal studies in two different species that both produced multi-organ tumor signals at all doses tested, with no safe threshold identified, and a plausible biological mechanism that explains why the pharmacological activation of PPARdelta might behave differently than the physiological activation you get from training.

The people who dismiss the cancer concern because of the doses are making a math argument that ignores the shape of the dose-response curve, which showed no floor. The people who say it definitively causes cancer in humans are extending animal data further than the evidence allows. Both positions are easier than the honest one, which is that anyone using this compound is operating inside a data gap that no existing study can close.

---

References

1. Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ 2009. Rat two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting, Abstract #895. Multi-organ tumors at all dose levels in Han Wistar rats including liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs. Source
2. Newsholme SJ, Dunsford WS, et al. 2009. Mouse two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting. Multi-organ tumor signal confirmed in mice, consistent with rat findings. Source
3. Ding Y, et al. 2021. AMPK phosphorylates PPARdelta at Serine 50, suppressing pro-tumorigenic transcriptional programs while preserving metabolic benefits. Journal of Biological Chemistry, 297:100954. Source
4. Reagan-Shaw S, Nihal M, Ahmad N 2008. Dose translation from animal to human studies revisited. FASEB Journal, 223:659-661. FDA-preferred body surface area normalization method for interspecies dose conversion. Source
5. Olson EJ, Pearce GL, Jones NP, Sprecher DL 2012. Human RCT, 268 subjects, up to 10 mg/day for 12 weeks. No serious adverse events but far too short for cancer assessment. Arteriosclerosis, Thrombosis, and Vascular Biology, 329:2289-2294. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness